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ABSTRACT 
 
COMPARISON OF ALBUTEROL DELIVERY BETWEEN HIGH FREQUENCY 
OSCILLATORY VENTILATION AND CONVENTIONAL MECHANICAL 
VENTILATION IN A SIMULATED ADULT LUNG MODEL USING DIFFERENT 
COMPLIANCE LEVELS  
By  
Waleed A. Alzahrani, BSRT 
 
BACKGROUND: Delivery of aerosol by pMDI has been described with conventional 
mechanical ventilation (CMV) but not with high frequency oscillatory ventilation (HFOV). The 
purpose of this study was to compare aerosol delivery to a simulated 75 kg adult with low 
compliance during both CMV and HFOV.  Since actuation of pMDI with inspiration is not 
feasible with HFOV, we investigated the impact of actuation timing only during CMV. 
 
METHOD: CMV (Respironics Esprit) and HFOV (Sensor Medics 3100B) ventilators 
with passover humidifiers and heated circuits were connected by 8 mm ID ETT and filter 
(Respirgard II, Vital Signs) to a test lung (TTL) with compliance settings of 20 and 40 ml/cm 
H2O in order to simulate a non compliant lung. Settings for CMV (VT 6 ml/kg, I:E 1:1, PEEP 20 
cm H2O, and RR 25/min), and HFOV (RR 5 Hz, IT 33%, ∆P 80 cm H2O and mPaw 35 cm H2O) 
were used, with similar mPaw on CMV and HFOV.  Parameters were selected based on 
ARDSnet protective lung strategy (Fessler and Hess, Respiratory Care 2007)  Eight actuations of 
albuterol from pMDI (ProAir HFA, Teva Medical) with double nozzle small volume spacer 
(Mini Spacer, Thayer Medical) placed between the ―Y‖ adapter and ETT at more than 15 sec 
intervals for each condition (n=3). During CMV, pMDI actuations were synchronized (SYNC) 
with the start of inspiration at more than 15 s, and nonsynchronized (NONSYNC) with 
actuations at 15 s intervals. Drug was eluted from the filter and analyzed by spectrophotometry 
(276 nm). Repeated measures ANOVA, pairwise comparisons and independent t- tests were 
performed at the significance level of 0.05.  
 
RESULTS: In all cases, aerosol delivery was greater with HFOV than CMV (p<0.05). 
Synchronizing pMDI actuations with the beginning of inspiration increased aerosol deposition 
significantly at compliance levels 20 ml/cm H2O and 40 ml/cm H2O (p=0.011 and p=0.02, 
respectively). Lung compliance and aerosol delivery are directly related. Increasing lung 
compliance to 40 ml/cmH2O improved aerosol delivery during CMV and HFOV (p<0.05). 
 
CONCLUSION: Albuterol deposition with pMDI was more than two fold greater with 
HFOV than CMV in this in-vitro lung model. Changing lung compliance has almost 2 fold 
impact on aerosol delivery during both modes of ventilation. Furthermore, synchronizing pMDI 
actuations during CMV improved aerosol delivery up to 4 fold.  
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Chapter I 
Introduction  
Pulmonary diseases with low lung compliance such as acute respiratory distress 
syndrome (ARDS), pneumonia, acute respiratory failure, atelectasis, and aspiration pneumonia 
are common reasons for admission to an adult intensive care unit (ICU) for mechanical 
ventilatory support. These diseases have one particular characteristic in common: all of them are 
characterized by having low lung compliance. Low lung compliance in adults can occur for 
many reasons such as the aspiration of fluids into the lungs, the loss of surfactant, or the collapse 
of the alveoli. Aspiration occurs when oropharyngeal or gastric material is misdirected into the 
lower respiratory tract. Following aspiration, the inhaled secretions are colonized by pathogens 
resulting in the development of pneumonia during which an acute inflammatory reaction occurs, 
which can result in granulomatous lesions or bronchiolitis (Müller, 2003). Eventually, the 
inflammatory reaction will cause a disease that will reduce the lung compliance such as ARDS.  
ARDS is a disease associated with low lung compliance that frequently requires 
admission to the ICU and the subsequent use of conventional mechanical ventilation (CMV) 
and/or high frequency oscillatory ventilation (HFOV). ARDS is characterized by activation of 
inflammation and coagulation that induces changes in the permeability of the alveolocapillary 
membrane. As a result protein-containing fluid shifts into the interstitial and alveolar space 
(David, et al., 2003). This leads to degradation of alveolar surfactant and to atelectasis formation, 
which results in increased intrapulmonary shunting and hypoxemia (Ragaller & Richter, 2010). 
Mismatch of ventilation and perfusion is further aggravated by microthrombosis of alveolar 
capillaries, resulting in increased partial pressure of carbon dioxide in the blood (PaCO2) and 
alveolar dead space (David, et al., 2003). 
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CMV support is one of the initial therapeutic modalities used to manage patients who 
have low lung compliance due to diseases such as ARDS, pneumonia, or atelectasis. Early CMV 
support strategies in these patients include increasing inspiratory time (TI), positive end-
expiratory pressure (PEEP), and the use of large tidal volumes (VT). The high pressures and high 
VT in ventilation are associated with increased transpulmonary pressure that results in a 
reduction of right ventricular preload (Jardin & Vieillard-Baron, 2003). These strategies may 
produce barotrauma and volutrauma, which may damage the pulmonary capillary endothelium 
and thus allow fluid and protein to accumulate in the interstitial space and alveoli (Brower & 
Brochard, 2006). In recent years, CMV strategies have emerged to reduce these complications. 
These strategies, which include the acute lung injury (ALI) and ARDS management protocol that 
uses CMV with high respiratory rate (RR) and low VT (Brower & Brochard, 2006), are used to 
prevent further lung injury and to avoid lung collapse and atelectasis caused by high PEEP 
levels. This strategy also uses low VT to avoid overdistension of the lung. Additionally, static 
pressure volume curves are used to determine lower and upper inflection points in order to apply 
the appropriate level of PEEP and end-inspiratory pressures (Wunsch & Mapstone, 2005).  
However, these approaches have limitations, especially when the pressure range between 
the upper and lower inflection points is too small to provide sufficient alveolar ventilation. 
Studies have shown that compartments with very long time constants (more than 8 seconds) may 
exist in patients with ARDS, and that such ―slow‖ compartments may comprise more than 10% 
of aerated lung volume (Fessler & Hess, 2007). Presently, avoiding high peak inspiratory 
pressures (PIP), large VT, and high inspiratory oxygen concentration is recommended (Malik, 
2003). Even with optimal use of CMV, progression of hypoxia and respiratory acidosis 
frequently occur (Fessler & Hess, 2007).  
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Another strategy to manage patients with low lung compliance diseases is through the use 
of HFOV, a type of ventilation developed to limit mechanical ventilator-induced lung injury 
(VILI) or damage (Derdak, et al., 2002). In HFOV, a diaphragm superimposes pressure 
oscillations on the mean airway pressure (mPaw) provided by continuous gas flow. This results 
in small VT at high RR with active exhalation. Lung injury is reduced by avoiding over inflation 
of compliant segments of the lung and collapse of less compliant lung segments (Mehta, et al., 
2004). Furthermore, HFOV improves oxygenation, reduces the need for supplemental oxygen, 
and improves outcomes (survival with or without severe chronic lung disease) in adults (Derdak, 
2003; Derdak, et al., 2002; Fort, et al., 1997; Mehta, et al., 2001).  
As this literature review shows, both CMV and HFOV have advantages and 
disadvantages in the management of ARDS. Usually, lung compliance is worsened with the 
severity of the lung disease, which makes it more difficult to manage. Exacerbating problems 
include overdistension of the lungs due to the stiffness and the low compliance of the lung. Thus, 
to protect the lungs, strategies for lung-protective ventilation have begun to emerge. HFOV 
appears to be ideal to support principles of lung-protective ventilation and provides a relatively 
high mPaw, which may recruit the lung more effectively than PEEP as typically set on a CMV 
(Ritacca & Stewart, 2003). It also provides small VT, which minimizes the risk of overdistension 
during inspiration and minimizes the opportunities for derecruitment during expiration. 
However, controversy about HFOV and its ability to achieve the goals of lung-protective 
ventilation still remains. One of the reasons behind this debate is the fact that the VT cannot be 
measured during HFOV (Fessler & Hess, 2007).  
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Some studies have compared HFOV and CMV in cases of low and different levels of 
lung compliance, though these comparisons have never been fully investigated. However, one 
study showed a statistically significant difference between the intervention and control groups in 
the total length of ventilator days (Wunsch & Mapstone, 2005). Overall, current studies have not 
provided enough evidence to conclude that high-frequency ventilation (HFV) reduces mortality 
or long-term morbidity in patients with ARDS when compared to CMV (Wunsch & Mapstone, 
2005). Furthermore, lung-protective CMV strategies are structured to limit alveolar 
overdistension through the use of small VT and low end-inspiratory pressures, and to avoid 
repeated end-expiratory alveolar collapse by using adequate PEEP (Downar & Mehta, 2006). 
This strategy has been associated with a 9% absolute reduction in mortality compared with a 
strategy that employed a higher VT (ARDSNet, 2000).  
Research shows that patients with low levels of compliance, such as adult patients with 
ARDS, also often receive inhaled bronchodilators (Garner, Wiest, & Bradley, 2000), although 
their benefits has not been well established. Because effectiveness of inhaled medications is 
dependent on delivery to the lung, it is important to determine how HFOV and CMV affect the 
delivery of inhaled medications in patients with low lung compliance. No studies have 
thoroughly investigated the use of a pressurized meter dose inhaler (pMDI) during HFOV or 
CMV to treat diseases that have low levels of lung compliance such as ARDS. The amount of 
aerosol deposition during HFOV and CMV in a simulated model will be determined in this 
study. Currently, ventilator manufacturers recommend disconnecting the patient from HFOV and 
applying manual ventilation during inhaled drug administration. This could potentially be 
detrimental to ARDS patients because the disconnection from HFOV in order to deliver pMDI 
medications may result in lung derecruitment (Garner, et al., 2000).  
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The purpose of this study is to compare albuterol delivery between HFOV and CMV in a 
simulated adult lung model with different compliance levels.  
Upon reviewing the literature, four important research questions arose:  
1. What is the amount of aerosol delivered from pMDI at two levels of compliance 
during HFOV? 
2. What is the amount of aerosol delivered from pMDI at two levels of compliance 
during CMV? 
3. Is there any difference in aerosol delivery between HFOV and CMV in a 
simulated adult lung model with different levels of compliance? 
4. What is the difference in aerosol delivery between synchronized puffs and 
unsynchronized puffs in a simulated adult lung model with different levels of 
compliance in the CMV groups?  
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Chapter II 
Review of Literature 
This literature review focuses on areas relevant to HFOV in adult patients, CMV in adult 
patients with ARDS, comparisons between HFOV and CMV in the management of ARDS, the 
relation of lung compliance to ARDS, how to manage ARDS with lung protective strategies 
(LPS), aerosol delivery using pMDI in CMV, and aerosol delivery using pMDI in HFOV. The 
studies and reviews collected for this review come from the following databases: Medline, 
Science Direct, Proquest, Ebsco Host, Web of Science, and PubMed. The search terms used were 
HFOV, CMV, ARDS, adult, aerosol delivery, pMDI, albuterol, and lung compliance. No 
published studies were found that compared aerosol delivery with HFOV versus CMV in the 
adult population. However, one published study was found that explored aerosol delivery in a 
pediatric HFOV model. Additionally, very few studies compared HFOV and CMV in the adult 
population with ARDS or low lung compliance diseases.  
ARDS 
Brower et al. (2001) published an article about the treatment of ARDS that improved the 
understanding of the pathogenesis of ARDS. They indicated that one of the clinical hallmarks of 
ARDS is the decrease in lung compliance that is caused by the flooding of alveoli, which 
increases surface tension at air-fluid interfaces and eventually causes atelectasis. The authors 
suggested that the standard supportive care for ALI/ARDS should now include a protective 
ventilatory strategy with low VT ventilation. They also indicated that results of anti-inflammatory 
strategies have been disappointing in clinical trials. 
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HFOV in Adults 
Mehta et al. (2004) reviewed patients treated with HFOV at three academic university-
affiliated ICUs since 1998 in three medical-surgical ICUs in Toronto, Canada. A total of 156 
adults were involved in the study. The mean partial pressure of oxygen in arterial blood (PaO2) / 
the fraction of inspired oxygen (FiO2) ratios and mean oxygenation index (OI) improved 
significantly with the application of HFOV. Significant changes in hemodynamics following 
HFOV initiation included an increase in central venous pressure, a reduction in cardiac output, 
and an increase in pulmonary artery occlusion pressure. The study concluded that HFOV has 
beneficial effects on PaO2/FiO2 ratios and OI, and may be an effective rescue therapy for adults 
with severe oxygenation failure. The study suggested that early institution of HFOV may be 
advantageous. 
Another study by Metha et al. (2001) evaluated the safety and efficacy of HFOV in adult 
patients with the ARDS and oxygenation failure. In an ICU and burn units of two universities 
teaching hospitals. Twenty-four adults were included in the study. The authors indicated  
observed the occurrence of changes in hemodynamic variables following HFOV initiation, these 
included an increase in pulmonary artery occlusion pressure and central venous pressure, and a 
reduction in cardiac output throughout the course of the study. They also indicated that there 
were no significant changes in systemic or pulmonary pressure associated with initiation and 
maintenance of HFOV. The authors concluded that HFOV has beneficial effects on oxygenation 
and ventilation, and may be a safe and effective rescue therapy for patients with severe 
oxygenation failure. Also they indicated that early institution of HFOV may be advantageous. 
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Chan et al. (2007) reviewed randomized controlled trials (RCT) and case series about 
HFOV and adult patients with ARDS. The authors found that what makes HFOV unique is its 
rapid delivery of small VT of gas and the application of high mPaw. This concept makes HFOV 
an ideal lung-protective ventilatory mode for the management of ARDS, as the high mPaw 
prevents cyclical derecruitment of the lung, and the small VT limits alveolar overdistension. In 
their review, Chan et al. identified two RCTs and 12 case series evaluating HFOV in adults with 
ARDS. In these studies, HFOV appeared to be safe and consistently improved oxygenation when 
used as a rescue mode of ventilation in patients with severe ARDS. The two RCTs comparing 
HFOV to CMV had encouraging results that led to an increasing use of HFOV in adults with 
ARDS. However, their study failed to show a mortality benefit of HFOV over CMV.  
 David et al. (2003) examined whether ARDS patients who failed to maintain oxygenation 
and CO2 removal on CMV can be safely transitioned to HFOV. They also examined whether 
HFOV use is efficacious. Their study was observational and included a 14-bed ICU of a 
university hospital. A total of 42 patients with ARDS were enrolled in the study. The study 
showed that at baseline the median PaO2/FiO2 ratio was 95. However, after 24 hours of HFOV, 
the PaO2/FiO2 ratio increased significantly to 165. Of the 42 patients, 18 (43%) had died by Day 
30. The study showed a significantly higher 30-day mortality rate in patients with at least 3 days 
of mechanical ventilation (MV) prior to HFOV (64%) and in patients without oxygenation 
improvement after 24 hours on HFOV (71%). It also showed that failure to improve oxygenation 
within 24 hours of HFOV is associated with high mortality. The study concluded that HFOV is 
an effective and safe method to ventilate ARDS patients. 
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 Ragaller and Richter (2010) examined different MV strategies for treating patients with 
ALI or ARDS. They emphasized on experimental and clinical data that can be applied to clinical 
practice. The authors indicated that one of the ARDS symptoms is substantial reduction in 
pulmonary compliance. They focused on VALI and how to reduce it using the protective 
ventilation strategy. The goals of this strategy are directed towards the prevention of further 
harm to the lungs through the use of a low VT and a high RR to prevent overdistension, 
barotraumas, and atelectasis. Furthermore, their study showed that protective MV is beneficial 
not only for the lungs but also for the heart. Their article concluded that the simple procedure of 
lung-protective ventilation, using reduced VT, a pressure limit, and a FiO2 as low as possible is 
the only known effective therapy that does not incur excessive risk. Thus, using lung-protective 
ventilation can effectively reduce the mortality rate of patients with ALI/ARDS.  
 Downar and Mehta (2006) reviewed the use of HFOV in adults with ARDS and found 
that MV for ARDS patients can exacerbate lung damage because of VILI. However, they 
suggested that HFOV may improve oxygenation in patients with ARDS, while limiting further 
lung injury associated with high ventilatory pressures and volumes delivered during CMV. They 
also indicated that no mortality benefit was established when using HFOV over CMV. 
Nevertheless, their review suggested that HFOV, compared with CMV, is a safe and effective 
ventilation strategy for adults with ARDS. They also indicated that HFOV may improve 
outcomes if used early in the course of ARDS or if used in certain populations. Downar and 
Mehta focused on the evidence supporting the use of HFOV in adults with ARDS including the 
goals of a lung-protective strategy. Their review indicated that a higher sustained mPaw would 
increase alveolar recruitment, which, in turn, would improve ventilation–perfusion matching and 
oxygenation. 
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Another review about the use of HFOV with adults, conducted by Ritacca and Stewart 
(2003), indicated that strategies aimed at preventing VILI, such as ventilating with low VT, can 
reduce mortality in patients with ARDS. The review also suggested that HFOV is ideal as a LPS 
for adult patients with ARDS. The authors indicated that the amount of gas that enters and exits 
the lung with each oscillation is frequently below the anatomic dead space. Despite this, gas 
exchange still occurs, and potential adverse effects of CMV, such as overdistension and the 
repetitive opening and closing of collapsed lung units, are arguably mitigated. Ritacca and 
Stewart reviewed the principles and practical aspects of HFOV, as well as the current evidence 
of the application of HFOV in adults with ARDS. They concluded that when HFOV is used early 
in ARDS, it will have, at least, an equivalent effect to that of CMV and may reduce mortality.  
Derdak, et al. (2002) conducted a multicenter, RCT study to compared the safety and 
effectiveness of HFOV with CMV in adults with ARDS. The authors indicated that ARDS 
patients managed by HFOV showed improvement in PaO2 / FiO2 when compared with patients 
managed by CMV. Their study also showed an improvement in the mortality rate with the 
HFOV group. The study concluded that HFOV is a safe and effective mode of ventilation for the 
treatment of ARDS in adults. 
Another review by Derdak (2003) indicated that using HFOV improved oxygenation in 
neonatal and pediatric respiratory failure and reduced the occurrence of VILI, without increasing 
barotrauma. The author also indicated that HFOV in patients failing CMV strategies have 
improved oxygenation in adult patients with severe ARDS. The review suggested that early (2 
days) initiation of HFOV is more likely to result in survival than delayed initiation (>7 days). 
The author indicated that HFOV is as effective and safe as CMV. 
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HFOV vs. CMV 
Wunsch and Mapstone (2005) compared HFOV with CMV for the treatment of ARDS by 
examining the outcomes of using the two ventilation therapies to treat ALI and ARDS in 
children and adults. They found two trials that fit their inclusion criteria: the first included 58 
children, and the second recruited 148 adults. Both trials used HFOV as the intervention and 
included variable use of lung-volume recruitment strategies. Wunsch and Mapstone’s review 
indicated that the intervention groups showed a trend toward 30-day less mortality. However, the 
authors also found that neither study had a statistically significant difference. Similarly, there 
was no statistically significant difference between the intervention and control groups for total 
number of ventilator days. The pediatric study showed a statistically significant reduction in the 
need for supplemental oxygen among survivors at the 30 days trend. Wunsch and Mapstone 
determined that there is not enough evidence to conclude HFOV reduces mortality or long-term 
morbidity in patients with ARDS. 
Another review, conducted by Fessler and Hess (2007), compared HFOV and CMV in 
adult patients with ARDS and found that HFOV can support gas exchange with much smaller VT 
than can be achieved with CMV. Additionally, the review found that HFOV provides more 
effective lung recruitment than CMV and may improve PaO2 in some patients as compared to 
CMV, although this improvement is often transitory. Nevertheless, the authors concluded that 
there is not enough evidence to indicate that survival in adults with ARDS is improved by 
HFOV. The available evidence does not support that pulmonary inflammation is reduced with 
HFOV in adult ARDS. Fessler and Hess suggested that the use of HFOV as a lung protective 
ventilator strategy needs more clinical trials to determine whether this approach is superior to 
lung protective ventilation using CMV.  
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Lung Protective Mechanical Ventilator Strategy for ARDS 
 Meade et al. (2008) studied the ventilation strategy using low VT, recruitment maneuvers, 
and high PEEP in ALI and ARDS. The purpose of the study was to compare an established low- 
VT ventilation strategy with an experimental strategy based on the original "open-lung 
approach," combining low VT, lung recruitment maneuvers, and high PEEP. The RCT involved 
30 ICU in Canada, Australia, and Saudi Arabia and was conducted between August 2000 and 
March 2006 and included 983 consecutive patients with ALI. At enrollment, 85% (n = 983) of 
the patients met the criteria for ARDS. The study concluded that using a multifaceted 
protocolized ventilation strategy designed to recruit and open the lung resulted in no significant 
difference in hospital mortality or barotrauma compared with an established low VT protocolized 
ventilation strategy in patients with ALI and patients with ARDS. 
Brower and Brochard (2006) reviewed the use of LPS with CMV for the management of 
ALI and ARDS and found that CMV can cause VILI, which may delay or prevent recovery in 
some patients. They discussed clinical trials that demonstrated improved clinical outcomes in 
patients who received lower VT and inspiratory airway pressures to prevent VILI from 
overdistension. The authors also indicated that experimental models suggest that VILI may occur 
from cyclic opening and closing of small bronchioles and alveoli, and that this can be reduced by 
applying PEEP. They indicated that some clinical studies suggested that clinical outcomes may 
be improved with the use of higher levels of PEEP, especially when compared to the outcomes 
of using CMV strategies. However, in these studies, higher PEEP was combined with lower VT 
and inspiratory airway pressures. Brower and Brochard also indicated that the physiologic 
rationale for using HFV is strong, but clinical trials are needed to demonstrate improved clinical 
outcomes with HFV when compared to lung-protective MV strategies. 
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Koutsoukou et al. (2009) investigated the effect of CMV on respiratory mechanics and 
blood gases using a LPS before the onset of ARDS. Nineteen patients with ARDS were stratified 
into two groups according to ARDS onset relative to the onset of MV. In group A, MV was 
applied at the onset of ARDS. In group B, MV was initiated before ARDS. The study showed 
that in group A, the PaO2/FiO2 ratio increased and respiratory system resistance decreased from 
early to late ARDS. In group B, static elastance of the respiratory system increased in the late 
stage. In both groups, PEEP application resulted in PaO2/FiO2 ratio and respiratory system 
resistance improvements. Their study concluded that ARDS patients ventilated using a LPS will 
show late alteration of respiratory mechanics if they were ventilated before ARDS onset. Their 
result suggests that history of MV affects subsequent progress of ARDS even when using a LPS. 
Pressurized Metered Dose Inhalers and CMVs 
Hess, Dillman, and Kacmarek (2003) studied aerosol bronchodilator delivery during MV. 
They compared the delivery of aerosol pMDI in both pressure control ventilation (PCV) and 
volume control ventilation. The objective of their study was to determine the effect of TI and 
inspiratory flow patterns on albuterol delivery by aerosol during MV using both a nebulizer and 
a pMDI. Their study evaluated two different levels of lung compliance, two different resistance 
levels, two different TI, and three different inspiratory flow patterns. Their study concluded that 
the nebulizer showed a significant difference in albuterol delivered for TI, flow pattern, and lung 
mechanics, which means that albuterol delivery by nebulizer is affected by TI and inspiratory 
flow patterns. For the pMDI, there were no significant differences in the amount of albuterol 
delivered for TI, flow pattern, or lung mechanics. These results indicate that when pMDI is used, 
the amount of albuterol delivered is not affected by the inspiratory flow pattern or TI. Thus, the 
pMDI is much more stable than a nebulizer when used with CMV. 
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Another study, conducted by Marik, Hogan, and Krikorian (1999), compared 
bronchodilator therapy delivery by nebulization and pMDI in 30 mechanically ventilated 
patients. Marik et al. studied albuterol delivery using a nebulizer, a pMDI, a spacer, and a right-
angle pMDI adaptor in MV patients. Urinary analysis was used to measure drug levels. First, five 
puffs of albuterol were delivered by pMDI with a small volume spacer. Second, five puffs of 
albuterol were delivered by pMDI using a right-angle adaptor. And third, 2.5 mg of albuterol was 
delivered by a nebulizer. Their study concluded that the three delivery systems varied markedly 
in their efficiency of drug delivery to the lung. However, this study confirmed that using a pMDI 
and spacer is an efficient method for delivering inhaled bronchodilators to the lung. 
Dhand et al. (1996) explored the efficacy of pMDIs in mechanically ventilated patients 
and sought to determine its optimal dose. They studied the response to increasing doses of 
albuterol administered by a pMDI and cylindrical spacer to 12 mechanically ventilated patients 
with chronic obstructive pulmonary disease (COPD). In the study, four, eight, and 16 puffs of 
albuterol were administered at 15-minute intervals. Rapid airway occlusion was performed 
before and at 5-minute intervals after albuterol administration for 80 minutes. Respiratory 
mechanics were measured for 60 minutes in another group of seven patients with COPD who 
received four puffs of albuterol. Their study found a significant decrease in airway resistance 
(Raw) after the administration of albuterol. The decrease in Raw with four puffs of albuterol was 
comparable to that observed with cumulative doses of 12 puffs and 28 puffs. The study indicated 
that the heart rate increased significantly after a cumulative dose of 28 puffs. The decrease in 
Raw was sustained for 60 minutes in the group that received four puffs of albuterol. They 
concluded that four puffs of albuterol given by a pMDI and spacer provided the best combination 
of bronchodilator effect and safety in stable mechanically ventilated patients with COPD. 
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Dhand and Tobin (1997) discussed inhaled bronchodilator therapy in mechanically 
ventilated patients. They concluded that the administration of inhaled drugs to mechanically 
ventilated patients is complicated by deposition of the aerosol particles in the ventilator circuit 
and the endotracheal tube (ETT). Their study showed that aerosol deposition in the lower 
respiratory tract of mechanically ventilated patients is lower than that of ambulatory patients. 
They also indicated that aerosol delivery involves several variables that might affect the delivery 
to mechanically ventilated patients. These include the type of nebulizer used, actuation of pMDI 
into an in-line chamber spacer, timing of actuation, ventilator mode, VT, circuit humidification, 
and duty cycle. Dhand and Tobin suggested that the bronchodilator effect obtained with four 
puffs of albuterol from a pMDI is comparable to that obtained with 6 to 12 times the same dose 
given by a nebulizer and is likely to be far more cost-effective. 
 Gay et al. (1991) investigated pMDI for bronchodilator delivery in intubated 
mechanically ventilated patients. They studied the efficacy of two bronchodilator aerosol 
delivery methods in 18 intubated mechanically ventilated patients with airway obstruction. In the 
first group, a pMDI was used to deliver albuterol. In the second group, a nebulizer with an 
updraft inhaler was used to deliver albuterol. The study was a single blind, randomized crossover 
design. The results revealed that treatment sequence, severity of obstruction, and bronchodilator 
responsiveness had no effect on relative efficacy. Albuterol caused a small but significant 
increase in heart rate that was similar following both delivery methods. Gay et al. concluded that 
bronchodilator aerosol delivery with pMDI provided a viable alternative to nebulizer therapy in 
intubated mechanically ventilated patients and may result in a cost savings to hospitals and 
patients. 
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Ari, Areabi, and Fink (2010) evaluated drug delivery from four aerosol generator 
devices—jet, vibrating mesh, ultrasonic nebulizers, and pMDI with spacer—at three locations in 
the circuit; between the ETT and the Y-piece, 15 cm from the Y-piece, and 15 cm from the 
ventilator in humidified and non-humidified circuits during adult CMV. Their study indicated 
that the vibrating-mesh nebulizer, ultrasonic nebulizer, and pMDI with spacer were most 
efficient when positioned 15 cm from the Y-piece with both non-humidified and 
heated/humidified circuits. They also found that all devices delivered approximately twofold 
more of the drug under non-humidified than under heated/humidified conditions when positioned 
15 cm from the Y-piece and 15 cm from the ventilator. The researchers also found that pMDI 
deposited a higher proportion of medication than the other aerosol generators in the non-
humidified circuit, and when they positioned it between the ETT and the Y-piece under 
humidified conditions, the percentage of drug delivered sharply decreased. Their study 
concluded that the optimal drug delivery efficiency during CMV depends on the aerosol 
generator used, the ventilator circuit, and the aerosol generator position.  
Aerosol Delivery With HFOV in a Pediatric Model 
Garner et al. (2000) assessed albuterol delivery by pMDI in a pediatric lung model 
ventilated by HFOV. The researchers used a set-up consisting of a HFOV and a pediatric lung 
simulator and used ventilator settings, lung compliance, and resistance values that were 
consistent with a pediatric patient with pulmonary disease. They administered albuterol pMDI 
with a spacer and actuator, which were placed proximal to the ETT. They placed a circuit filter 
proximal to the lung simulator and another filter in the circuit's expiratory limb. The filters 
collected the albuterol exiting the ETT and any albuterol lost in the expiratory limb, respectively. 
Albuterol administration was repeated at different operating frequencies and TI using both an 
 17 
actuator and a spacer. The study showed that albuterol delivery to the lung simulator was <1% of 
the administered dose regardless of the operating frequency (f), TI, or use of a spacer or actuator. 
Albuterol lost in the expiratory limb ranged from 3.28% to 14.89% of the administered dose. The 
study concluded that albuterol delivery by pMDI in a pediatric model of HFOV is negligible, 
regardless of the operating f, TI, or use of a spacer or actuator. 
After reviewing the literature, it is clear that ARDS affects lung compliance and Raw due 
to the etiology of the ARDS disease. Lung compliance is directly related to the severity of 
ARDS: if the disease gets worse, lung compliance will decrease, and if the patient gets better, the 
lung mechanics will improve. In respiratory diseases with low lung compliance and high Raw 
such as ARDS, a lung protective ventilatory strategy with low VT should be implemented to 
avoid damaging the lungs. As the literature shows, studies that have compared CMV support and 
HFOV support in the management of ARDS in adults have shown incongruent results. One 
review article failed to prove that the use of HFOV improves survival rates among patients with 
ARDS (Ritacca & Stewart, 2003). Additionally, available evidence does not support the claim 
that HFOV reduces pulmonary inflammation in ARDS patients (Fessler & Hess, 2007). Another 
study indicated that using HFOV is as effective and safe as the use of CMV (Derdak, 2003). 
Overall, the literature indicated that HFOV is an effective lung protective ventilatory strategy 
and a safe method to ventilate ARDS patients with low lung compliance. Studies have shown 
that HFOV consistently improves oxygenation and may reduce mortality. Combining this 
strategy of ventilation with effective delivery of aerosolized respiratory medications could help 
in improving the condition. During the review of literature, no studies were found that examined 
the effectiveness of aerosol delivery using pMDI with HFOV in the adult population with 
ARDS. However, the effectiveness of aerosol delivery with CMV has been explored and 
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according to studies discussed in this chapter, nebulized albuterol with CMV is affected by the 
TI, inspiratory flow pattern, and lung mechanics, including lung compliance and Raw. In 
comparison, the literature shows that when using pMDI with CMV, the amount of albuterol 
delivered is not affected by inspiratory flow pattern or TI, which indicates that pMDI is much 
more stable when compared to a nebulizer. The literature also indicated that using pMDI and 
spacer with CMV is an efficient method for delivering inhaled bronchodilators to the lung.  
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Chapter III 
Methods and Materials 
Research Design  
This in vitro study utilized a quasi-experimental design. The study consisted of three 
main groups: the unsynchronized CMV, the synchronized CMV, and the HFOV groups. In all 
groups, two different levels of compliance (20 L/cm H2O and 40 L/cm H2O) were used. The 
methods and materials utilized in this study were used to answer the following questions: 
1. What is the amount of aerosol delivered from pMDI at two levels of compliance during 
HFOV? 
2. What is the amount of aerosol delivered from pMDI at two levels of compliance during 
CMV? 
3. Is there any difference in aerosol delivery between HFOV and CMV in a simulated adult 
lung model with different levels of compliance? 
4. What is the difference in aerosol delivery between synchronized puffs and 
unsynchronized puffs in a simulated adult lung model with different levels of compliance 
in the CMV groups? 
Lung Model 
A portable dual test lung (Training/Test Lung [TTL] PneuView systems, dual adult lung 
simulator, Michigan Instruments, Grand Rapids, MI, United States) was used to simulate the 
breathing parameters of an adult patient. The TTL simulates adult lungs that can hold a residual 
capacity typical of adult human lungs. The TTL uses a steel alloy spring, which is stretched 
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during inflation of the lung, to set and adjust the two levels of lung compliance (20 ml/cm H2O 
and 40 ml/cm H2O). The Raw was simulated by using a fixed-orifice flow resistor that was 
placed in the two branches of the TTL tubes. A resistance of 20 cm H2O/L/sec was used in this 
study. The resistors offer accurate simulation at both upper and lower Raw in exact accordance 
with the American Society for Testing and Materials standards. The resistors represent the 
parabolic flow characteristics of the human airway. This resistance was constant during all runs 
and consistent with the resistance levels reported for adult patients who are candidates for 
HFOV. 
Study Groups  
Three groups of tests were included in the study. In the unsynchronized CMV and the 
synchronized CMV groups, a CMV with a volume control mode (CMV-VC) was used 
(Respironics Esprit Ventilator Philips/Respironics, Murrysville, PA) with a standard heated wire 
circuit and a humidification chamber (Fisher & Paykel, Auckland, New Zealand), connected to a 
8 mm ETT (Mallinckrodt, PA, United States) that was attached to the TTL lung simulator using 
a collecting filter (Respirgard II™ Filter, Vital Signs, Totowa, NJ). Figure 1 shows the pMDI 
spacer and how it is set-up in the study.  
 
 
 
Figure 1. The placement of the pMDI spacer in the patient-ventilator circuit in all groups 
(Modified with permission from Thayer Medical). 
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The HFOV group of tests used the HFOV (Sensormedics 3100B, Loma Linda, CA, 
United States) with a HFOV patient-ventilator circuit and a humidification chamber (Fisher & 
Paykel, Auckland, New Zealand), connected to a 8 mm ETT (Mallinckrodt, PA, United Sates) 
that was attached to the TTL lung simulator using a collecting filter.  
Figure 2 shows the experiment set-up of the study. 
Figure 2. A diagram of the experimental set-up of the study used with CMV and HFOV. 
Ventilators Settings 
The Unsynchronized and Synchronized CMV groups settings. The ventilator settings 
used for the CMV group were obtained from the recommendations in Fessler and Hess (2007). 
They included using an ideal body weight of 75 kg with a delivered VT of 6 ml/kg on a volume 
control mode, I:E of 1:1, PEEP 20 cm H2O, a rate of 25 breaths per minute, and a humidified 
temperature of 37°C.  
The HFOV group settings. The settings used for the HFOV were obtained from the 
guidelines in Fessler and Hess. (2007).These guidelines were implemented to direct routine 
clinical care for operating HFOV. Fessler and Hess recommended these guidelines to optimize 
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lung-protective characteristics of HFOV. The settings they used included a pressure amplitude 
(delta-P) of 80 cm H2O, a 33% TI, a f of 5 Hz, and a mPaw of 35 cm H2O, at bias gas flow of 30 
L/min at 50% oxygen. The present study used the following HFOV settings: a f of 5 Hz, a TI of 
33%, and a delta-P of 80 cm H2O. Usually, patients are started with an mPaw either the same or 
2 – 3 cm H2O above the mPaw found during CMV. For the purpose of comparison, this study 
used an mPaw of 35 cm H2O. The humidified FiO2 was set at 50%, the TI was 33%, and the 
humidified temperature was 37°C. The delta-P used in this study provided an excellent chest 
wall movement simulation with the TTL.  
Data Collection  
The ventilators in all groups were allowed to stabilize for 15 minutes before data collection, and 
circuit calibration was performed before each test run. The pMDI canister (Proair HFA, TEVA 
Pharmaceuticals, Horsham, PA) was inserted into a pMDI spacer (Mini spacer, Thayer Medical, 
uscan, AZ), which was placed between the ETT and the Y adaptor of the ventilator circuit. The 
collecting filter was placed between the TTL lung and the ETT to collect any albuterol aerosol 
particles. The collecting filters were replaced with each test. Albuterol delivery was determined 
by rinsing the circuit filter with 0.1 N HCl. The filter was manually rinsed for 3 minutes to elute 
the drug. The albuterol concentration was then detected with a spectrophotometer (Beckman UV 
& Visible Light Spectrophotometer, Fullerton, CA) at 276 nm.  
pMDI Delivery 
 The administration of eight albuterol pMDI puffs (one puff every 15 seconds) was 
repeated three times, with each ventilator group at each level of compliance (n=3). Each canister 
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was primed before administering aerosolized albuterol. All drug administration in all runs during 
the experiment was performed by one investigator to assure consistency. 
Unsynchronized pMDI actuations with CMV. In the unsynchronized CMV group, the 
administration of the pMDI puffs was performed every 15 seconds regardless of the phase of 
respiration that was occurring at the time. There was no synchronization between the pMDI puffs 
and the inspiratory phase in this group.  
 Synchronized pMDI actuations with CMV. In the synchronized CMV group, 
administration of the pMDI puffs was synchronized with the inspiratory phase by allowing more 
than 15 seconds between puffs.  
 pMDI actuations with HFOV. In the HFOV group, the administration of the pMDI puffs 
was performed every 15 seconds.  
Data Analysis 
The amount of drug deposited on the filter was quantified as a percentage of the emitted 
dose. The descriptive statistics including the means and standard deviations were calculated for 
each condition tested in the study. An independent sample t-test was conducted to evaluate 
differences in the mean inhaled percentage of the dose delivered by pMDI between two 
compliance levels. A repeated measure ANOVA was utilized to determine differences among the 
means for unsynchronized CMV, synchronized CMV, and HFOV. A pairwise comparison 
among the means for unsynchronized CMV, synchronized CMV, and HFOV at each compliance 
level was used in this study. All data analysis was performed using the predictive analysis 
software (PASW) statistics (version 18), and statistical significance was defined as p < 0.05. 
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The research methods were directed by the study questions: What is the amount of 
aerosol delivered from pMDI at two levels of compliance during HFOV? What is the amount of 
aerosol delivered from pMDI at two levels of compliance during CMV? Is there any difference 
in aerosol delivery between HFOV and CMV in a simulated adult lung model with different 
levels of compliance? What is the difference in aerosol delivery between synchronized puffs and 
unsynchronized puffs in a simulated adult lung model with different levels of compliance in the 
CMV groups? The HFOV used in this study was the sensormedics 3100B and it is considered the 
only adult HFOV available in the market. A lung simulator with ability to control lung 
compliance and Raw was used in this study. Aerosol deposition was measured using a 
spectrophotometer and the analysis was performed using PASW statistics (version 18).  
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Chapter IV 
Results 
This study compared CMV with HFOV in order to quantify the amount of aerosol 
delivery to a patient receiving those types of MV modalities. In this chapter, the aerosol 
deposition results of all groups are shown first, comparing the two levels of lung compliance 
within the groups. Second, a comparison of the aerosol deposition results between the 
corresponding levels of lung compliance from all groups will be explored. Table 1 shows the 
descriptive statistics of the three comparison test groups. 
Table 1 
 
The Mean and Standard Deviation of Inhaled Drug Mass Percent Obtained From pMDI With 
Each Ventilator at Each Level of Compliance (20 ml/cm H2O and 40 ml/cm H2O)  
 
 
Compliance Level 
(ml/cm H2O) 
 
CMV 
Unsynchronized  
 
 
CMV Synchronized 
 
 
HFOV 
 
20 
 
 
3.14 ± 0.62 
 
7.44 ± 0.44 
 
19.80 ± 3.64 
40 
 
3.73 ± 1.27 14.37 ± 2.46 35.08 ± 4.20 
p value .506 .009 .009 
 
 
The Unsynchronized CMV Group 
 The independent t-test shows that there was no significant statistical difference between 
compliance level 20 ml/cm H2O and compliance level 40 ml/ H2O ( p = .506) when there was no 
synchronization of pMDI delivery with the inspiratory phase in the unsynchronized CMV group. 
As shown in Table 1, the mean aerosol deposition in the unsynchronized CMV group with a 
compliance level of 20 ml/cm H2O was 3.14 ± 0.62 %, while the mean aerosol deposition at a 
compliance level of 40 ml/cm H2O was 3.73 ± 1.27%. 
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The Synchronized CMV Group 
The independent t-test shows that there was a significant statistical difference between 
compliance level 20 ml/cm H2O and compliance level 40 ml/cm H2O (p = .009) when there was 
synchronization of pMDI delivery with the inspiratory phase in the synchronized CMV group. 
As shown in Table 1, the mean aerosol deposition in the synchronized CMV with a compliance 
level of 20 ml/cm H2O was 7.44 ± 0.44%, while the mean aerosol deposition with a compliance 
level of 40 ml/cm H2O was 14.37 ± 2.46%. 
The HFOV Group 
The independent t-test shows that there was a significant statistical difference between 
compliance level 20 ml/cm H2O and compliance level 40 ml/cm H2O (p = .009). The mean 
aerosol deposition in the HFOV group with a compliance level of 20 ml/cm H2O was 19.80 ± 
3.64%, while the mean aerosol deposition with a compliance level of 40 ml/cm H2O was 35.08 ± 
4.20%. 
Comparison of the HFOV, the Synchronized CMV, and the Unsynchronized CMV Groups 
at Compliance Level 20 ml/cm H2O 
 The repeated measures ANOVA results showed that there was a statistical significance (p 
= .014) in the comparison of the HFOV, the synchronized CMV, and the unsynchronized CMV 
groups at the 20 ml/cm H2O compliance level.  
As shown in Figure 3, the post-hoc multiple comparisons showed that at the 20 ml/cm 
H2O compliance level, there was a significant statistical difference between the unsynchronized 
CMV group and the synchronized CMV group (p = .011). Comparing the unsynchronized CMV 
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group and the synchronized CMV group with the HFOV group showed a significant statistical 
difference (p = .014 and p = .022, respectively). 
Comparison of the HFOV, the Synchronized CMV, and the Unsynchronized CMV Groups 
at Compliance Level 40 ml/cm H2O 
 Comparing the level 40 ml/cm H2O compliance from the HFOV, the synchronized CMV, 
and the unsynchronized groups using the repeated measures ANOVA showed that there was a 
statistical significance (p = .01). Post-hoc multiple comparisons showed that at the 40 ml/cm 
H2O compliance level, there was a significant statistical difference between the unsynchronized 
CMV group and the synchronized CMV group (p = .020). Additionally, a comparison of the 
unsynchronized CMV group with the HFOV group showed a significant statistical difference (p 
= .010). Furthermore, comparing the synchronized CMV group with the HFOV group showed a 
significant statistical difference (p = .019). Figure 3 shows the results of the independent t-test 
and the post-hoc multiple comparisons at compliance levels 20 ml/cm H2O and 40 ml/cm H2O. 
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Figure 3. The inhaled dose percent obtained from the unsynchronized CMV, Synchronized CMV 
and HFOV groups at lung compliance level of 20 ml/cm H2O and 40 ml/cm H2O. 
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Chapter V 
Discussion 
 The main purpose of this study was to investigate the aerosol delivery with HFOV and 
compare it to the aerosol delivery with CMV at different compliance levels. The questions that 
were investigated in this study are: What is the amount of aerosol delivered from pMDI at two 
levels of compliance during HFOV? What is the amount of aerosol delivered from pMDI at two 
levels of compliance during CMV? Is there any difference in aerosol delivery between HFOV 
and CMV in a simulated adult lung model with different levels of compliance? What is the 
difference in aerosol delivery between synchronized puffs and unsynchronized puffs in a 
simulated adult lung model with different levels of compliance in the CMV groups? The study 
results revealed significantly different amounts of aerosol deposition when using pMDI albuterol 
with HFOV when compared with CMV. The following discussion will look more closely at 
observations made during the study and will evaluate how this study compares with results found 
in the literature. This chapter concludes with a discussion of the limitations of this study, the 
future research needed, and a conclusion for this study. 
Observations 
After all comparisons, this study showed that there was no significant statistical 
difference between compliance level 20 ml/cm H2O and compliance level 40 ml/ H2O in the 
unsynchronized pMDI delivery during the inspiratory phase of the unsynchronized CMV group. 
The mean aerosol deposition at compliance level 20 ml/cm H2O was 3.14 %, while the mean 
aerosol deposition at compliance level 40 ml/cm H2O was 3.73 %. This was expected due to the 
fact that unsynchronization with the inspiratory phase may cause the delivery of pMDI to occur 
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during the expiratory phase, thus making the aerosol travel away from the patient. This was 
proven when the synchronization of pMDI delivery during the inspiratory phase in the 
synchronized CMV group was conducted.  
In the synchronized delivery of pMDI during the inspiratory phase of the CMV group, 
the study showed that there was a significant statistical difference between 20 ml/cm H2O and 40 
ml/cm H2O. The mean aerosol deposition in the synchronized CMV group with a compliance 
level of 20 ml/cm H2O was 7.44%. This is more than double the amount of deposition that 
occurred when the delivery of pMDI was not synchronized with the inspiratory phase. 
Furthermore, the mean aerosol deposition at compliance level 40 ml/cm H2O was 14.37%, which 
is more than triple the deposition recorded for the unsynchronized CMV group. These results are 
not surprising because aerosol was delivered during the inspiration phase only, thus ensuring that 
aerosol particles would be carried towards the lung and not away from it.  
Furthermore, the results of this study is different than those of other researchers who 
synchronized pMDI delivery with CMV (Ari, et al., 2010). Ari and her colleagues had a mean 
deposition of albuterol sulfate distal to the ETT of 7.6 ± 1.3%. In this study, the mean deposition 
was 7.44 ± 0.44% and 14.37 ± 2.46% at compliance levels 20 ml/cm H2O and 40 ml/cm H2O, 
respectively. The differences are contributed to factors related to the settings used in both studies 
including the flow rate, minute ventilation (VE) and I:E ratio. In this study, a flow rate of 50 
liters per minute was used while Ari et al. used a flow rate of 60 liters per minute. The slower 
flow used in this study caused more aerosol deposition to occur. Other factors that contributed to 
this difference in aerosol deposition between the two studies are the VE and I:E ratio used in 
both studies. In this study, a VE of 11.250 liters per minute and I:E ratio of 1:1 were used while 
Ari et al. used a VE of 7.5 liters per minute and I:E ratio of 1:3. The higher VE and I:E ratio used 
 31 
in this study allowed for more volume of air to be delivered in a single minute thus contributing 
to the increase in aerosol delivery.  
The difference in the amount of deposition between 20 ml/cm H2O and 40 ml/cm H2O in 
both the unsynchronized CMV and synchronized CMV groups can be explained by the status of 
the lungs. At compliance level 20 ml/cm H2O, the lung is stiffer and air has more difficulty 
reaching the lungs. Volumes measured by the ventilator at a compliance level of 20 ml/cm H2O 
were lower than those measured during a compliance level of 40 ml/cm H2O. This finding 
indicates that aerosol deposition is affected significantly by the level of lung compliance and by 
the respiratory phase in which the medication is delivered. This result is confirmed by comparing 
the amount of aerosol deposition that occurs between levels 20 ml/cm H2O and 40 ml/cm H2O of 
lung compliance. In both groups, the amount of aerosol deposition was larger at the compliance 
level of 40 ml/cm H2O and smaller at the compliance level of 20 ml/cm H2O. This can be 
explained by the amount of air entering the lungs during each level of compliance. Even though 
expired VT was not measured during the lab tests for this study, upon observation, the expired VT 
was higher when the lung was more compliant and lower when the lung was less compliant. This 
was consistent in all test runs performed with CMV. These tests confirm that the level of lung 
compliance has a major impact on the aerosol deposition for the reasons mentioned earlier. 
In the HFOV group, there was a significant statistical difference in aerosol delivery 
between compliance level 20 ml/cm H2O and compliance level 40 ml/cm H2O. The mean aerosol 
deposition in the HFOV group with a compliance level of 20 ml/cm H2O was 19.80%, while the 
mean aerosol deposition at a compliance level of 40 ml/cm H2O was 35.08%. The HFOV group 
deposition results were extremely higher, and this was not expected. The initial expectation was 
that there would be minimal deposition, especially when compared to the CMV group, because 
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HFOV has a continuous bias flow and active exhalation. The continuous and high bias flow 
causes the development of more turbulent flow in the HFOV circuit, which should cause aerosol 
deposition to be lower (Niederer, Leuthold, Bush, Spahn, & Schmid, 1994). The active 
exhalation in HFOV also might contribute to a decrease in aerosol deposition (Herridge & 
Slutsky, 1996), because it might prevent albuterol particles from reaching the collecting filter 
placed proximal to the lung simulator, which could enhance the loss in the expiratory limb of the 
circuit. For these reasons, the expectation was that the deposition of aerosol in the HFOV group 
would be lower than that of the CMV group.  
However, the test results showed the opposite. The deposition of aerosol in the HFOV 
group was much higher than in the CMV group. The high deposition of aerosol in the HFOV 
group may be explained by the distinctive flow profiles and gas exchange mechanisms of HFOV. 
The oscillations generated by the extreme frequencies and the high flow rates in HFOV produce 
unique flow velocity profiles that cause gas to mix in the airways. These unique flow velocity 
profiles are responsible for gas exchange and transport in HFOV(Chang, 1984). The flow 
velocity profiles of HFOV include bulk convection, Taylor dispersion, asymmetric velocity 
profiles (coaxial flow velocities), pendelluft phenomena, cardiogenic mixing, molecular 
diffusion, and collateral ventilation (Chang, 1984). The following sections explain these profiles 
in detail. 
Direct bulk flow. This movement has a major role in ventilating the proximal airways. 
Some alveoli located in the proximal tracheobronchial tree receive a direct flow of inspired air. 
This results in gas exchange by traditional mechanisms of convective or bulk flow (Krishnan & 
Brower, 2000). 
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Longitudinal/Taylor dispersion. Taylor dispersion can result in a mixing of fresh and 
residual gases along the front of a flow of gas through a tube. According to Pillow (2005) ―the 
longitudinal dispersion of tracer molecules in a diffusive process is augmented by radial 
transport mechanisms when laminar flow is applied in both the absence or presence of turbulent 
eddies and secondary swirling motions. Some fresh gas may mix with gas from alveoli, 
increasing the amount of gas exchange that would occur from simple bulk flow‖. 
Asymmetric velocity profiles. In this profile, air in the center of the airway lumen moves 
into the lung while air that is close to the outer airway wall moves out toward the mouth. This 
movement occurs because air closest to the tracheobronchial wall has a lower velocity than air in 
the center of the airway lumen. This phenomenon is apparent at the airway bifurcations where 
gas is transported to the alveoli through the center of the airway, while exhaled gas is expired via 
the outer airway wall. This mechanism promotes axial gas exchange with expired alveolar gas, 
thus playing an important role in the longitudinal convective transport mechanisms during 
HFOV (Pillow, 2005). 
Pendelluft phenomena. In this profile, gas mixing occurs between adjacent alveoli with 
incongruent time constants. This means that air swings between lung regions. The varying Raw 
and compliance in different lung regions cause some regions of the lungs to fill and empty more 
rapidly than others. This happens especially in regions that are close to each other(Chan, et al., 
2007). 
Cardiogenic mixing. In this profile, researchers presume that heart contractions 
contribute to gas mixing, especially in lung regions that are close to the heart. The cardiogenic 
mechanism is caused by the strong contractions of the heart, which, in turn, cause the lung 
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regions near the heart to generate air flow (Pillow, 2005). However, the role of cardiogenic 
mixing during HFOV still needs more investigation (Slutsky & Brown, 1982). 
Molecular diffusion. This mechanism occurs in the smallest bronchioles and alveoli, 
near the alveolocapillary membranes. Molecular diffusion can occur at the alveolar level 
secondary to the added kinetic energy from the oscillations. This mechanism has an important 
role in explaining how gas exchange occurs at the alveolar level. In the alveolar regions, gas 
velocities approximate zero as a result of the total cross-sectional area in this zone. The dominant 
mechanism for gas mixing in this zone is molecular diffusion, with net transport of gas best 
described by Fick's law (Chang, 1984; Pillow, 2005). 
Collateral ventilation. Collateral ventilation occurs between neighboring alveoli, and it 
allows air movement between air sacs in the lungs. Researchers presume that this mechanism 
improves gas exchange during HFOV because of air flowing between asynchronous adjoining 
airways (Armengol, Jones, & King, 1985; Chan, et al., 2007).  
Figure 4 shows the gas transport mechanisms and pressure damping that occur during 
HFOV. The mechanisms include the direct bulk flow, the longitudinal/Taylor dispersion, the 
asymmetric velocity profiles, the pendelluft phenomena, cardiogenic mixing, molecular 
diffusion, and collateral ventilation. 
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Figure 4. Gas transport mechanisms and pressure damping during HFOV. (Modified with 
permission from Wolters Kluwer Health). 
These distinctive flow profiles and gas exchange mechanisms in HFOV can help us 
understand how air is transported to and from the lungs and thus help to understand how aerosol 
particles are carried when administered in HFOV. An additional factor that might contribute to 
the increase in aerosol deposition found in this study during the HFOV group is the usage of the 
HFA pMDI and the usage of the dual spray pMDI actuator. The HFA pMDI particle size 
produced and the geometry of the actuator orifice allow for the formation of a cloud containing 
particles of the drug that is easier to inspire and thus increase the chances of more drug delivery. 
Also, the use of the patented dual-spray nozzle delivery system in the pMDI spacer resulted in a 
bidirectional aerosol plume, thus improving delivery of the pMDI medication. Due to the dual-
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spray nozzle, upon actuation of the pMDI canister, the drug plume sprays in both directions, 
minimizing the amount of drug impinging on the walls of the tubing; thus the evaporation of 
pMDI propellant is enhanced.  
The repeated measure ANOVA comparison of the HFOV, the synchronized CMV, and 
the unsynchronized CMV groups at the compliance level of 20 ml/cm H2O and 40 ml/cm H2O 
showed statistically significant results. Post-hoc multiple comparisons showed that in 
compliance level 20 ml/cm H2O and 40 ml/cm H2O, there was significant statistical difference 
among all groups in each correspondent level of compliance. At the level of 20 ml/cm H2O 
compliance, significant statistical difference between the unsynchronized CMV group and the 
synchronized CMV group was found. This can be explained because of the synchronization of 
pMDI puffs with the inspiratory phase allowed more aerosol to travel to the patient as compared 
to when the pMDI is not synchronized with the inspiratory phase. Comparing the 
unsynchronized CMV group with the HFOV group showed a significant statistical difference. 
Furthermore, comparing the synchronized CMV group with the HFOV group showed a 
significant statistical difference as well. Again, this can be explained by the distinctive flow 
profiles and gas exchange mechanisms of the HFOV as explained earlier.  
Comparing the compliance level of 40 ml/cm H2O with the HFOV, the synchronized 
CMV, and the unsynchronized groups showed a statistical significance. Post-hoc multiple 
comparisons showed that at a compliance level of 40 ml/cm H2O, there was a significant 
statistical difference between the unsynchronized CMV group and the synchronized CMV group. 
This can be explained because of the synchronization of pMDI puffs with the inspiratory phase 
allowed more aerosol to travel to the patient as compared to when the pMDI is not synchronized 
with the inspiratory phase. Also, another reason that contributes to this is the level of compliance 
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of the lungs. At a compliance level of 40 ml/cm H2O, the lungs are more flexible and compliant. 
This allows a higher volume of air to be delivered to the lungs with less pressure compared to the 
compliance level of 20 ml/cm H2O. The increased amount of compliance creates less resistance 
and therefore less turbulent flow and more aerosol deposition. Comparing the unsynchronized 
CMV group with the HFOV group and the synchronized CMV group with the HFOV group 
showed a significant statistical difference as well and can be explained by the same reasons 
illustrated previously in the level 20 ml/cm H2O compliance.  
In the literature, there are no studies published about using aerosol pMDI in adult patients 
receiving HFOV. Also, there is no study available comparing HFOV and CMV in the delivery of 
aerosolized medications using pMDI in the adult population. This study was the first to compare 
albuterol delivery between HFOV and CMV in a simulated adult lung model using different 
compliance levels.  
However, A single study in the literature published by Garner, Wiest, & Bradley (2000) 
investigated albuterol delivery using pMDI in a pediatric lung model. Their results were different 
from this study’s results. Garner et al. found that the aerosol delivery with HFOV in a pediatric 
lung model is negligible. The contrasting results between the two studies may be due to lung 
size: we used an adult lung model in which higher volumes are delivered and they used a 
pediatric lung model in which lower volumes are delivered. Also, this study used a f of 5 Hz, 
which is actually lower than the 10 Hz used by Garner et al.  
Another factor that might account for the differences in results was our use of a patented 
dual-spray nozzle delivery system. Garner et al. did not specify if they used a dual-spray nozzle 
delivery system. Additionally, each study used a different type of pMDI. In this study, an HFA 
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pMDI was used, while Garner et al. used a CFC pMDI. A final difference between the studies 
centers on the measurement of aerosol deposition. Garner et al. used a high performance liquid 
chromatography to measure the amount of aerosol deposition. In this study, a spectrophotometer 
was used to acquire the amount of aerosol deposition. These differences in study design could 
account for the incongruent results between this study and that of Garner et al.  
Clinical Implications of the Study 
The clinical implications of this study include: 
1. The delivery of albuterol via pMDI and a spacer is possible with HFOV. 
2. Albuterol deposition with pMDI was more than twofold greater with HFOV than with CMV. 
3. Synchronizing pMDI actuations during CMV improved aerosol delivery up to fourfold.  
4. The level of lung compliance is a factor affecting the deposition of aerosol therapy (Albuterol 
deposition is increased with better levels of lung compliance). 
Limitations 
Limitations that might prevent this study from being applied in a clinical situation include 
the fact that this was an in vitro study. This study does not address the clinical efficacy of 
albuterol delivery during CMV and HFOV. Also, in this study, a homogenous test lung was 
used. Human test subjects would show heterogeneous lungs with various lung conditions. 
Furthermore, this study did not explore the effect of different ventilator settings on albuterol 
delivery to adults with low lung compliance. Other limitations of this study are the factors that 
were not studied, such as the use of different pMDI spacers, the use of dry air, the use of 
different levels of resistance, and the use of different positions of the pMDI delivery within the 
patient-ventilator circuit. 
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Avenues for Future Research  
The effect of Raw on the delivered aerosol using pMDI should be explored in future 
studies to determine how aerosol particles from a pMDI are affected by changes in Raw. Also, 
future studies are needed to explore the effects of changing the ventilator setting on the delivered 
aerosol particles. Furthermore, future studies should explore the effect of different spacers and 
different aerosol generators on aerosol delivery during HFOV. 
Conclusion 
Albuterol deposition with pMDI was more than twofold greater with HFOV than with 
CMV in this in vitro lung model. Changing lung compliance has an almost twofold impact on 
aerosol delivery during both modes of ventilation. Synchronizing pMDI actuations during CMV 
improved aerosol delivery up to fourfold. 
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